|Day Low/High||5.71 / 6.08|
|52 Wk Low/High||4.60 / 11.72|
A roundup of biotech names with actions pending at the FDA in coming weeks.
I've added to my positions in these names on yesterday's intraday silliness.
Top-line Data Expected in 3Q2018
Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the August 2018 expiration.
Sector M&A activity is likely to pick up next year benefiting the space.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
We are coming my favorite part of earnings season -- when these small-caps report.
The housing market will continue to improve over the next few years due to pent up demand.
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.
Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.
Zogenix, Flexion, Dynavax and Progenics all have potential upside on these events.
Zogenix, Flexion, Dynavax and Progenics all have potential upside on upcoming events.
Study results show that treatment with AZEDRA produced clinically meaningful and durable responses across multiple study endpoints, including radiographic tumor response, tumor biomarker response, and overall survival
I am working incrementally into some small stocks with great long-term value.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.